Karanbir S Pahil
Karanbir S Pahil
1Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA USA
1,#,
Morgan S A Gilman
Morgan S A Gilman
2Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA USA
2,#,
Vadim Baidin
Vadim Baidin
1Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA USA
1,
Thomas Clairfeuille
Thomas Clairfeuille
3Departments of Immunology, Infectious Disease and Ophthalmology (I2O), Medicinal Chemistry and Lead Discovery, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
3,
Patrizio Mattei
Patrizio Mattei
3Departments of Immunology, Infectious Disease and Ophthalmology (I2O), Medicinal Chemistry and Lead Discovery, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
3,
Christoph Bieniossek
Christoph Bieniossek
3Departments of Immunology, Infectious Disease and Ophthalmology (I2O), Medicinal Chemistry and Lead Discovery, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
3,
Fabian Dey
Fabian Dey
3Departments of Immunology, Infectious Disease and Ophthalmology (I2O), Medicinal Chemistry and Lead Discovery, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
3,
Dieter Muri
Dieter Muri
3Departments of Immunology, Infectious Disease and Ophthalmology (I2O), Medicinal Chemistry and Lead Discovery, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
3,
Remo Baettig
Remo Baettig
3Departments of Immunology, Infectious Disease and Ophthalmology (I2O), Medicinal Chemistry and Lead Discovery, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
3,
Michael Lobritz
Michael Lobritz
3Departments of Immunology, Infectious Disease and Ophthalmology (I2O), Medicinal Chemistry and Lead Discovery, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
3,
Kenneth Bradley
Kenneth Bradley
3Departments of Immunology, Infectious Disease and Ophthalmology (I2O), Medicinal Chemistry and Lead Discovery, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
3,
Andrew C Kruse
Andrew C Kruse
2Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA USA
2,✉,
Daniel Kahne
Daniel Kahne
1Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA USA
1,✉
1Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA USA
2Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA USA
3Departments of Immunology, Infectious Disease and Ophthalmology (I2O), Medicinal Chemistry and Lead Discovery, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
Subject terms: Cryoelectron microscopy, Mechanism of action, Transporters, Target validation, Antibiotics
© The Author(s) 2024
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.